Back to search
FDAFDA · Food and drugs·Recall number D-0309-2021

Romidepsin Injecton, 27.5 mg/5.5 mL (5 mg/mL) Rx Only, 5.5 ml vial, Teva Pharmaceuticals USA, Inc. NDC 0703-4004-01

Published March 24, 2021 · Recall initiated: March 4, 2021

Summary

FDA records drug Class III recall D-0309-2021, published March 24, 2021 and initiated March 4, 2021. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 1,416 vials; Lot: Lot # 31328184C, exp. date 11/2021 Lot # 31327686C, exp. date 08/2021 Lot # 31327685C, exp. date 08/2021. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurity/Degradation Specifications: Out-of-specifications results observed for impurities during stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Distributed Nationwide in the USA.
Lot
Lot # 31328184C, exp. date 11/2021 Lot # 31327686C, exp. date 08/2021 Lot # 31327685C, exp. date 08/2021
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Romidepsin Injecton, 27.5 mg/5.5 mL (5 mg/mL) Rx Only, 5.5 ml vial, Teva Pharmaceuticals USA, Inc. NDC 0703-4004-01 recalled?

Yes. FDA published recall D-0309-2021 on March 24, 2021. Reported hazard: Failed Impurity/Degradation Specifications: Out-of-specifications results observed for impurities during stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter